Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

NCT05722418 is registered in ClinicalTrials.gov with Caribou Biosciences, Inc. as lead sponsor.

NCT NCT05722418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05722418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Lead sponsor
Caribou Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 6, 2023
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma